| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
Membrane proteins and lipid bilayers are the primary targets. This surfactant is widely used to stabilize and solubilize membrane proteins for structural analysis techniques such as crystallization and cryo-electron microscopy (cryo-EM).
|
|---|---|
| ln Vitro |
A biochemical reagent called hexaethylene glycol monotetradecyl ether can be utilized in life science research as an organic substance or biological material.
The activity of Hexaethylene glycol monotetradecyl ether is typically measured by its critical micelle concentration (CMC), ability to solubilize membrane proteins without denaturation, and effectiveness in extracting proteins from lipid bilayers in cell-free extraction assays. |
| ln Vivo |
There is no specific in vivo activity data available for this compound. It is used exclusively as an in vitro biochemical reagent for protein extraction, purification, and stabilization, rather than as a therapeutic or probe for animal studies.
|
| Enzyme Assay |
There is no specific enzyme/receptor binding protocol for this compound. A standard protocol for protein solubilization involves adding Hexaethylene glycol monotetradecyl ether at a concentration above its CMC (e.g., 0.5-2% w/v) to a suspension of membrane-containing material (e.g., cell lysate or isolated membranes), incubating on ice for 30-60 minutes with gentle mixing, then centrifuging to separate solubilized proteins from insoluble debris.
|
| Cell Assay |
There is no specific cell-based protocol for this compound. In cell lysis protocols for membrane protein extraction, Hexaethylene glycol monotetradecyl ether can be added directly to cell pellets at a final concentration of 0.5-2% (w/v) in a buffer containing protease inhibitors, followed by incubation on ice and centrifugation to obtain the solubilized protein fraction.
|
| Animal Protocol |
There is no standard in vivo animal protocol for this compound. It is not intended for use in live animals, as it is a detergent used in vitro.
|
| ADME/Pharmacokinetics |
General PK properties for this compound are not applicable. As a nonionic detergent, it is not used as a drug. Formulation is typically as a solid or in aqueous buffers.
|
| Toxicity/Toxicokinetics |
General toxicity for nonionic detergents is considered moderate. At working concentrations (0.1-2%), Hexaethylene glycol monotetradecyl ether can be cytotoxic to cells if used in vivo, but in biochemical applications, it is considered safe with proper handling. Standard lab safety precautions (gloves, goggles) should be used.
|
| Additional Infomation |
3,6,9,12,15,18-hexaoxotrichodo-1-ol is a polyethylene glycol.
Hexaethylene glycol monotetradecyl ether is a research-grade nonionic detergent widely used in membrane protein biochemistry. Its ability to solubilize and stabilize membrane proteins makes it an essential tool for structural biology, particularly for crystallization studies. This product is for research use only. |
| Molecular Formula |
C26H54O7
|
|---|---|
| Molecular Weight |
478.70
|
| Exact Mass |
478.387
|
| CAS # |
5157-04-0
|
| PubChem CID |
78833
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
0.97 g/cm3
|
| Boiling Point |
544.7ºC at 760mmHg
|
| Melting Point |
32-33ºC
|
| Flash Point |
283.2ºC
|
| Index of Refraction |
1.457
|
| LogP |
4.779
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
30
|
| Heavy Atom Count |
33
|
| Complexity |
332
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCO
|
| InChi Key |
CMOAVXMJUDBIST-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C26H54O7/c1-2-3-4-5-6-7-8-9-10-11-12-13-15-28-17-19-30-21-23-32-25-26-33-24-22-31-20-18-29-16-14-27/h27H,2-26H2,1H3
|
| Chemical Name |
2-[2-[2-[2-[2-(2-tetradecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethanol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0890 mL | 10.4450 mL | 20.8899 mL | |
| 5 mM | 0.4178 mL | 2.0890 mL | 4.1780 mL | |
| 10 mM | 0.2089 mL | 1.0445 mL | 2.0890 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
